Lineage Cell Therapeutics Inc
F:BT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lineage Cell Therapeutics Inc
F:BT3
|
US |
Intrinsic Value
The intrinsic value of Lineage Cell Therapeutics Inc (BT3) under the Base Case is 0.0003 EUR per share. Compared with the current market price of 0.831 EUR, the stock appears Overvalued by 100% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Lineage Cell Therapeutics Does
Lineage Cell Therapeutics is a biotechnology company that develops cell-based medicines, with a focus on using living cells to replace or repair damaged tissue. Its main work is in regenerative medicine, especially programs for eye disease and spinal cord-related conditions. The company does not sell consumer products; it sells science, drug candidates, and development rights that could become future treatments.
- Headquarters
- United States of America US
- Employees
- 75
- IPO date
- Mar 5, 1992
Earnings Waterfall
Lineage Cell Therapeutics Inc
The intrinsic value for Lineage Cell Therapeutics Inc (BT3) under the Base Case is 0.0003 EUR.
Compared with the current market price of 0.831 EUR, the stock appears Overvalued by 100% .